



SUGGESTED FORMULA

Diphenhydramine HCL 30mg/mL / Hydrocortisone 10mg/mL / Tripelemnamine HCL 20mg/MI Alcohol Gel, Preserved, Veterinary, Equine

Version number: 1.0

Volume or quantity: 100 mL

Diphenhydramine Hydrochloride, USP (DI160)	3gm
Hydrocortisone Micronized, USP (CO137)	1gm
Tripelemnamine Hydrochloride, USP (T1120)	2gm
Propylene Glycol, USP (PR130)	1.7mL
Hydroxypropyl Methylcellulose, USP (H1128)	2gm
Menthol, USP (ME111)	0.5gm
Alcohol 70% (Aqueous Ethanol Solution)	50mL
Preserved Water (Benzalkonium Chloride 0.01%)	Q.S.100mL

***Do not use heat when preparing this formula**

SUGGESTED COMPOUNDING PROCEDURES

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weigh and/or measure each ingredient
3. Dissolve the Menthol in Propylene Glycol
4. Dissolve Micronized Hydrocortisone in the Menthol mixture and mix well
5. Dissolve Diphenhydramine Hydrochloride and Tripelemnamine Hydrochloride in Alcohol Solution 70% mixing well
6. Combine the Hydrocortisone, Diphenhydramine Hydrochloride and Tripelemnamine mixture and mix well
7. Add the preserved water to the active component mixture using about 50% of the final volume
8. Stir the mixture from Step#7, using a stirrer to create a vortex, and gradually sift the Hydroxypropyl Methylcellulose until all components are dissolved and homogenous
9. Cover the mixture with plastic wrap and allow to gel
10. Bring to final volume with preserved water and stir carefully so that air bubbles are not introduced.
11. Package and label

12. Suggested Quality assessments:
 - a. color
 - b. texture
 - c. container
 - d. Label - auxiliary labels, storage, BUD, compounded medication

Store in light resistant air-tight container, at controlled room temperature

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date estimated to be 30 days *Per CompoundingToday.com Formula # 2188*

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

8/18 JD